BioCentury
ARTICLE | Company News

Athera, Boehringer Ingelheim deal

December 15, 2014 8:00 AM UTC

Athera said Boehringer declined to exercise its exclusive, 2013 option to PC-mAb, a human mAb against phosphorylcholine that is in Phase I testing to treat patients with cardiovascular disease at an...